Aslan, OnurYaylali, Y. T.Yildirim, S.Yurtdas, M.Senol, H.Ugur-Yildiz, M.Ozdemir, M.2025-05-102025-05-1020161076-02961938-272310.1177/1076029614546327https://doi.org/10.1177/1076029614546327https://hdl.handle.net/20.500.14720/14947Yurtdas, Mustafa/0000-0002-0516-9206; Yildirim, Sinan/0000-0001-8191-168XSafety issues have been raised about dabigatran. We aimed to investigate the occurrence of safety outcomes in patients who had atrial fibrillation and a risk of stroke. We analyzed 439 patients prescribed dabigatran (n = 220) or warfarin (n = 219). Ischemic stroke occurred in 15 (6.8%) patients in the warfarin group versus 5 (5.2%) patients in the 110-mg group versus 1 (0.8%) patient in the 150-mg dabigatran group (P = .015). Intracranial hemorrhage occurred in 6 (2.7%) patients in the warfarin group versus 3 (2.4%) patients in the 150-mg dabigatran group (P = .104). Death from any cause occurred in 10 (4.6%) patients in the warfarin group versus 1 (1.0%) patient in the 110-mg dabigatran group (P = .005). Dabigatran was associated with less ischemic stroke and death from any cause than warfarin. Dabigatran may be a better option for stroke prophylaxis, where recommended monitoring with warfarin is suboptimal.eninfo:eu-repo/semantics/openAccessDrug MonitoringHemorrhageMyocardial InfarctionStrokeThromboembolismArticle222Q2Q214715225115764WOS:000370068600005